In TRAIL/TNF-resistant prostate cancer cells, pre- or co-treatment to17-AAG with TRAIL/TNF is known to induce high levels of apoptosis (103) through inhibition of the NF-κB or Akt cell survival pathways (104, 105). This evidence concerns the gene TNFSF10 and prostate carcinoma.